Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study

The Lancet Infectious Diseases

Volumn 17, Issue 12, 2017, Pages 1293-1302

  Kavanagh, Kimberley ^a   Pollock, Kevin G ^b   Cuschieri, Kate ^e   Palmer, Tim ^c   Cameron, Ross L ^b   Watt, Cameron ^b   Bhatia, Ramya ^c   Moore, Catherine ^e   Cubie, Heather ^c   Cruickshank, Margaret ^f   Robertson, Chris ^a,b,d  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b HEALTH PROTECTION SCOTLAND   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

^e ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; CHILD; CROSS-SECTIONAL STUDY; DRUG EFFICACY; FEMALE; HEALTH PROGRAM; HERD IMMUNITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SCOTLAND; UTERINE CERVIX CANCER; WART VIRUS; YOUNG ADULT; IMMUNOLOGY; PAPILLOMAVIRUS INFECTION; PRESCHOOL CHILD; PROCEDURES; VACCINATION;

ADOLESCENT; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; SCOTLAND; VACCINATION;

EID: 85030329926     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30468-1     Document Type: Article

References (35)

1. Cuschieri, K, Brewster, DH, Williams, AR, et al. Distribution of HPV types associated with cervical cancers in Scotland and implications for the impact of HPV vaccines. Br J Cancer 102 (2010), 930–992.
2. Drolet, M, Benard, E, Boily, MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 15 (2015), 565–580.
3. Kavanagh, K, Pollock, KG, Potts, A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 110 (2014), 2804–2811.
4. Cameron, RL, Kavanagh, K, Pan, J, et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009–2013. Emerg Infect Dis 22 (2016), 56–64.
5. Pollock, KG, Kavanagh, K, Potts, A, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 111 (2014), 1824–1830.
6. Brotherton, JM, Fridman, M, May, CL, Chappell, G, Saville, AM, Gertig, DM, Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 377 (2011), 2085–2092.
7. Mesher, D, Soldan, K, Lehtinen, M, et al. Population-level effects of human papillomavirus vaccination programs on infections with nonvaccine genotypes. Emerg Infect Dis 22 (2016), 1732–1740.
8. Malagon, T, Drolet, M, Boily, MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12 (2012), 781–789.
9. Taylor, S, Ryser, M, Mihalyi, A, van Effelterre, T, Response letter regarding the letter to the editors by Brown et al. Hum Vaccin Immunother 12 (2016), 1943–1946.
10. Moscicki A-B, Harper D, Naud P, et al, eds. HPV-16/18 AS04-adjuvanted vaccine: sustained immunogenicity against HPV-31 and HPV-45 non-vaccine oncogenic types up to 9·4 years follow-up. Proceedings of the International Papillomavirus Society—30th International Papillomavirus Conference; Lisbon, Portugal; Sep 17–21, 2015. Abstract HPV15-0620.
11. Mesher, D, Cuschieri, K, Hibbitts, S, et al. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation. J Clin Pathol 68 (2015), 135–140.
12. Dunne, EF, Naleway, A, Smith, N, et al. Reduction in human papillomavirus vaccine type prevalence among young women screened for cervical cancer in an integrated US healthcare delivery system in 2007 and 2012–2013. J Infect Dis 212 (2015), 1970–1975.
13. Mesher, D, Panwar, K, Thomas, SL, Beddows, S, Soldan, K, Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open, 6, 2016, e009915.
14. Soderlund-Strand, A, Uhnoo, I, Dillner, J, Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study. Cancer Epidemiol Biomarkers Prev 23 (2014), 2757–2764.
15. Chow, EP, Danielewski, JA, Fehler, G, et al. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infect Dis 15 (2015), 1314–1323.
16. Markowitz, LE, Liu, G, Hariri, S, Steinau, M, Dunne, EF, Unger, ER, Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics, 137, 2016, e20151968.
17. NSS ISD. Trends in HPV immunisation uptake rates for S2 routine cohort by the end of the school year and one year later; by NHS Board. http://www.isdscotland.org/Health-Topics/Child-Health/publications/data-tables.asp?id=1781#1781, 2012 (accessed Sept 15, 2017).
18. Sinka, K, Kavanagh, K, Gordon, R, et al. Achieving high and equitable coverage of adolescent HPV vaccine in Scotland. J Epidemiol Community Health 68 (2014), 57–63.
19. Health Protection Scotland. National Surveillance System for Human Papillomavirus Infection and Related Disease in Scotland. http://www.hps.scot.nhs.uk/resourcedocument.aspx?resourceid=3130, 2008 (accessed Sept 15, 2017).
20. Kavanagh, K, Sinka, K, Cuschieri, K, et al. Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact. BMC Infect Dis, 13, 2013, 519.
21. Palmer, TJ, McFadden, M, Pollock, KG, et al. HPV immunisation and cervical screening—confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study. Br J Cancer 114 (2016), 582–589.
22. Scottish Government. Scottish Index of Multiple Deprivation: background and methodology. http://www.gov.scot/Topics/Statistics/SIMD/BackgroundMethodology, 2012 (June 15, 2017).
23. International Agency for Research on Cancer. Biological agents: a review of human carcinogens, 2012, World Health Organization, Lyon, France.
24. Arbyn, M, Snijders, PJ, Meijer, CJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?. Clin Microbiol Infect 21 (2015), 817–826.
25. Arbyn, M, Tommasino, M, Depuydt, C, Dillner, J, Are 20 human papillomavirus types causing cervical cancer?. J Pathol 234 (2014), 431–435.
26. Brisson, M, Jit, M, Boily, MC, et al. Modelling estimates of the incremental effectiveness and cost-effectiveness of HPV vaccination. http://www.who.int/immunization/sage/meetings/2016/october/07_Modelling_HPV_immunization_strategies.pdf, 2016 (accessed Sept 15, 2017).
27. Bosch, FX, Robles, C, Diaz, M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 13 (2016), 119–132.
28. Franco, EL, Cuzick, J, Hildesheim, A, de Sanjose, S, Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24:suppl 3 (2006), 171–177.
29. Ronco, G, Dillner, J, Elfstrom, KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383 (2014), 524–532.
30. Khan, MJ, Castle, PE, Lorincz, AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97 (2005), 1072–1079.
31. Bhatia R, Kavanagh K, Cubie H, et al, eds. HPV test performance in vaccinated women. European Research Organisation on Genital Infection and Neoplasia Conference; Salzburg, Austria; June 15–18, 2016.
32. Wentzensen, N, Schiffman, M, Palmer, T, Arbyn, M, Triage of HPV positive women in cervical cancer screening. J Clin Virol 76 (2016), S49–S55.
33. Cruickshank, ME, Pan, J, Cotton, SC, et al. Reduction in colposcopy workload and associated clinical activity following HPV catch-up vaccination programme in Scotland: an ecological study. BJOG 124 (2017), 1386–1393.
34. NSS ISD. Scottish Cervical Screening Programme: annual uptake data. https://www.isdscotland.org/Health-Topics/Cancer/Publications/2016-09-06/Annual_uptake_data.xlsx, 2016 (Sept 15, 2017).
35. Simms, KT, Smith, MA, Lew, JB, Kitchener, HC, Castle, PE, Canfell, K, Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries. Int J Cancer 139 (2016), 2771–2780.